Brian Slomovitz, MD
Disclosures: Consulting Fee-AstraZeneca|Consulting Fee-Eisai, Inc.|Consulting Fee-Abbvie (Relationship has ended)|Consulting Fee-Eli Lilly and Company (Relationship has ended)|Consulting Fee-Genentech, Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-GlaxoSmithKline|Grant or research support-Merck and Company, Inc.|Consulting Fee-Novartis AG (Relationship has ended)|Consulting Fee-karyopharm (Relationship has ended)|Consulting Fee-myriad (Relationship has ended) - 07/10/2022
No Bio Available.